الولايات المتحدة · منصات وبيانات · Morningstar

HUTCHMED Announces Closing of KRAS-EGFR-Antibody Conjugate Therapy License to GSK Outside China

نشره Morningstar · الولايات المتحدة منذ 8 س

Limited (“ HUTCHMED ” or the “Company”) (Nasdaq/AIM:HCM; HKEX:13) today announces that further to its announcement on September 3, 2026 and following the completion of customary…

اقرأ المقال كاملًا على Morningstar سجّل الدخول للحفظ

يعرض MarketNews العنوان والملخص كما نشرتهما الوسيلة الإعلامية. المقال الكامل متوفر على موقع الناشر. (www.morningstar.com)

يستحق القراءة أيضًا

The Motley Fool

Oracle Calls Force Majeure Already?

MarketWatch

Bull markets tend to peak with a whimper, not a bang — but a 15% correction for the S&P 500 may be next

MarketBeat

vTv Therapeutics Highlights Cadisegliatin’s Phase III Push to Tackle Type 1 Hypoglycemia

Seeking Alpha

Oil prices end lower in volatile session amid reports of U.S.-Iran diplomacy

Investing.com

NextDC shares plunge 42% to a near nine-year low after outlook cut

Yahoo Finance